Dr. Reddy's Laboratories, Inc. (RDY)'s Announces Start of Phase II Study with the CETP Inhibitor, DRL-17822 in Dyslipidemia Patients

9/2/2011 9:52:31 AM

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories (NYSE: RDY) announced the initiation of dosing with DRL-17822 in patients with diagnosis of type II dyslipidemia. DRL-17822 is a selective, orally bioavailable inhibitor of cholesteryl ester transfer protein (CETP), for the treatment and/or prevention of dyslipidemia, atherosclerosis and associated cardiovascular disease.

Read at BioSpace.com

Read Article at

Related Companies

News Categories

• BioSpace.com

• Dr. Reddy's Laboratories Ltd.

• Dr. Reddy's Laboratories, Inc.

• Clinical - Phase II

• Clinical - Phase II (World)